In its first-ever FDA approval, Switzerland’s Idorsia has snagged the regulatory green light for Quviviq (daridorexant), a potential blockbuster treatment for adults with insomnia. Source: Drug Industry Daily

Bayer and Mammoth Biosciences have announced a deal in which Bayer will shell out $40 million now and potentially up to $1 billion over time for the use of Mammoth’s…

A federal judge has thrown out Amarin’s complaint against Hikma Pharmaceuticals over the latter’s alleged patent infringement by its generic version of Vascepa (icosapent ethyl). Source: Drug Industry Daily

A federal judge in Texas has ruled that the FDA must by the end of this month make public 12,000 pages of the data it used to make decisions about…

France’s Sanofi and UK-based Exscientia have struck a deal potentially worth $5.2 billion to develop up to 15 new therapies for cancer and immunology indications using Exscientia’s artificial intelligence-based drug…

Tirzepatide, Eli Lilly’s potential dual-molecule blockbuster for type 2 diabetes (T2D), should be priced at $5,500 to $7,500 per year to be a cost-effective therapeutic option, according to the Institute…

The FDA will soon decide whether Eli Lilly’s and Innovent Biologics’ immunotherapy sintilimab can get the go-ahead in the U.S. for the treatment of lung cancer. Source: Drug Industry Daily

In a collaboration potentially valued at $1.9 billion, Amgen is teaming up with Cambridge, Mass.-based Generate Biomedicines to develop protein therapeutics for up to five clinical targets. Source: Drug Industry…

Bristol Myers Squibb’s potentially groundbreaking monoclonal antibody for advanced melanoma could win FDA approval in the next few months. Source: Drug Industry Daily

Sales of Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) have been exceedingly low. Source: Drug Industry Daily